Drug Trial Radar · NCT02232893
Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy
Last checked: Nov 19, 2026Latest source record: Jun 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Sep 2014
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Tsumura USAIndustry
- Sponsor type
- Industry
- Collaborators
- Cato Research
- First posted
- Sep 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TU-100 is a gastrointestinal drug produced from the three botanical raw materials, Asian ginseng, Zanthoxylum fruit (Japanese pepper), and ginger, based on proprietary aqueous decoction and granulation technology. The aim of this study is to assess the effect of TU-100 on post-operative quality of life during the 4 week postoperative period after straight, hand-assisted, or robot-assisted laparoscopic colectomy. Optimal efficacy parameters for subsequent outcome studies also will be explored.
Conditions
- Postoperative Ileus
Interventions
Daikenchuto (TU-100)Drug
Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
PlaceboDrug
Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality of Life After Surgery Based on Gastrointestinal Quality of Life Index (GIQLI) Global Score From Baseline to Visit 4.Time frame: Baseline and 15 days
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Los Angeles Site
Los Angeles, California
Aurora Site
Aurora, Colorado
Weston Site
Weston, Florida
Atlanta Site
Atlanta, Georgia
Chicago Site
Chicago, Illinois
Metairie Site
Metairie, Louisiana
Burlington, MA Site
Burlington, Massachusetts
Coon Rapids Site
Coon Rapids, Minnesota
Minneapolis Site
Minneapolis, Minnesota
Jackson Site
Jackson, Mississippi
Cleveland Site
Cleveland, Ohio
Burlington, VT Site
Burlington, Vermont
Spokane Site
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.